BD Begins CFO Transition, Reports Preliminary Q4 Results

BD (Becton, Dickinson and Company) announced a transition plan under which executive VP and CFO Chris DelOrefice will leave the company on Dec. 5, 2025 to pursue a new professional opportunity.

The company began a search to identify a permanent successor. Vitor Roque, senior VP of finance, business units, and corporate financial planning and analysis was named interim CFO and will take the role once DelOrefice departs.

“Chris has been an important part of our Executive Leadership Team over the past four years as we delivered on our BD 2025 strategy and transformed our portfolio to lead in the evolving healthcare landscape,” said Tom Polen, chairman, CEO, and president of BD. “As we transition, Vitor brings extensive knowledge of the company having served in a broad range of finance leadership roles over his two decades at BD across our regions, business units and segments while also supporting key acquisitions. His strong finance and leadership capabilities position him well to serve as interim CFO as we continue to deliver on our strategic goals.”

BD also provided selected unaudited preliminary results for Q4 and full year fiscal 2025 (ended Sept. 30, 2025).

Unaudited Q4 revenue was about $5.9 billion, representing an increase of about 8.3% over the prior year. Full-year unaudited revenue was about $21.8 billion, which marks growth of about 8.2% over the previous fiscal year.

The company said it expects to deliver full year adjusted diluted earnings per share (EPS) at or above the midpoint of its previous issued guidance.

“While we continue to navigate a dynamic macro environment that had a greater than anticipated impact this quarter in areas we have been closely monitoring, specifically Pharmaceutical Systems vaccines and Biosciences academic and government research, we delivered strong growth across multiple areas including the BD Interventional segment, Advanced Patient Monitoring and Medication Delivery Solutions,” said Polen. “Looking ahead, we continue to execute on our strategy and are taking further action to unlock value, including investments in areas of opportunity to drive growth and continued margin momentum. I look forward to sharing more on our New BD strategy and expectations for fiscal 2026 on our upcoming earnings call.”